Using Drosophila melanogaster to identify chemotherapy toxicity Genes

Genetics

Volumn 198, Issue 1, 2014, Pages 31-43

  King, Elizabeth G ^a,b   Kislukhin, Galina ^a   Walters, Kelli N ^a   Long, Anthony D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARRIER PROTEIN; GEMCITABINE; METHOTREXATE; MITOMYCIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; PROTEIN MSH2; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE RRM2; RIBONUCLEOTIDE REDUCTASE RRM2B; SOLUTE CARRIER FAMILY 7A INPP4A; SOLUTE CARRIER FAMILY 7A INPP4B; SOLUTE CARRIER FAMILY 7A NALCN; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DROSOPHILA PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; REPRESSOR PROTEIN; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; TIN PROTEIN, DROSOPHILA; TRANSACTIVATOR PROTEIN; TRANSPOSON;

ADVANCED INTERCROSS LINE; ALLELE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; DRUG TOXICITY; FEMALE; GENE SEGREGATION; GENETIC ASSOCIATION; HAPLOTYPE; MALE; NONHUMAN; ORTHOLOGY; PATHOGENESIS; QUANTITATIVE TRAIT LOCUS; QUANTITATIVE TRAIT LOCUS MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICOGENETICS; TRANSPOSON; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; FERTILITY; GENETICS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DEOXYCYTIDINE; DNA TRANSPOSABLE ELEMENTS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; FERTILITY; MITOMYCIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; REPRESSOR PROTEINS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; TRANS-ACTIVATORS;

EID: 84908003427     PISSN: 00166731     EISSN: 19432631     Source Type: Journal    
DOI: 10.1534/genetics.114.161968     Document Type: Article

References (26)

1. ALBEROLA, V., C. SARRIES, R. ROSELL, M. TARON, R. PENAS et al., 2004 Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin Lung Cancer 5: 360-365.
2. BIRNEY, E., T. D. ANDREWS, P. BEVAN, M. CACCAMO, Y. CHEN et al., 2004 An overview of Ensembl. Genome Res 14: 925-928.
3. BOAMAH, E. K., A. BREKMAN, M. TOMASZ, N. MYEKU, M. Figueiredo-Pereira et al., 2010 DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. Chem Res Toxicol 23: 1151-1162.
4. EKHART, C., V. D. DOODEMAN, S. RODENHUIS, P. H. M. SMITS, J. H. BEIJNEN et al., 2008 Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. harmacogenet Genomics 18: 515-523.
5. GURUBHAGAVATULA, S., G. LIU, S. PARK, W. ZHOU, L. SU et al., 2004 XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601.
6. GUSELLA, M., F. PASINI, C. BOLZONELLA, S. MENEGHETTI, C. BARILE et al., 2011 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol 71: 437-444.
7. HO, G. P. H., S. MARGOSSIAN, T. TANIGUCHI and A. D. D'andrea, 2006 Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Molecular and Cellular Biology 26: 7005-7015.
8. HONG, W., K. WANG, Y.-P. ZHANG, J.-Y. KOU, D. HONG et al., 2013 Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. J Zhejiang Univ Sci B 14: 207-215.
9. KALARI, K. R., S. J. HEBBRING, H. S. CHAI, L. LI, J.-P. A. KOCHER et al., 2010 Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach. BMC Genomics 11: 357.
10. KIM, Y., J. KOH, B. SHIN, K. AHN, B. CHOI et al., 2002 An antisense construct of full-length human RAD50 cDNA confers sensitivity to ionizing radiation and alkylating agents on human cell lines. Radiat Res 157: 19-25.
11. KO, J.-C., M.-S. TSAI, S.-H. WENG, Y.-H. KUO, Y.-F. CHIU et al., 2011 Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol 255: 327-338.
12. KWON, W. S., S. Y. RHA, Y. H. CHOI, J. O. LEE, K. H. PARK et al., 2006 Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 16: 429-438.
13. LI, H., H. SHI, H. WANG, Z. ZHU, X. LI et al., 2010 Crystal structure of the two N-terminal RRM domains of Pub1 and the poly(U)-binding properties of Pub1. J Struct Biol 171: 291-297.
14. MARING, J. G., F. M. WACHTERS, M. SLIJFER, J. M. MAURER, H. M. BOEZEN et al., 2010 Pharmacokinetics of gemcitabine in nonsmall-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 66: 611-617.
15. METHAROM, E., P. GALETTIS, S. MANNERS, M. JELINEK, W. LIAUW et al., 2011 The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. Asia Pac J Clin Oncol 7: 65-74.
16. ROQUES, C., Y. COULOMBE, M. DELANNOY, J. VIGNARD, S. GROSSI et al., 2009 MRE11-RAD50-NBS1 is a critical regulator of FANCD2 stability and function during DNA double-strand break repair. EMBO J 28: 2400-2413.
17. SI, S., Q. LIAO, Y. ZHAO, Y. HU, Q. ZHANG et al., 2011 Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines. Chin Med J (Engl) 124: 419-422.
18. STEFFENSEN, K. D., M. Waldstrøm and A. JAKOBSEN, 2009 The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19: 820-825.
19. SUGIYAMA, E., S.-J. LEE, S. S. LEE, W.-Y. KIM, S.-R. KIM et al., 2009 Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet 24: 553-556.
20. SUN, L., S. WANG, C. HU and X. ZHANG, 2010 Regulation of cell proliferation and apoptosis through fibrocystin-prosaposin interaction. Arch Biochem Biophys 502: 130-136.
21. TANAKA, M., M. JAVLE, X. DONG, C. ENG, J. L. ABBRUZZESE et al., 2010 Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 116: 5325-5335.
22. TANAKA, M., T. OKAZAKI, H. SUZUKI, J. L. ABBRUZZESE and D. LI, 2011 Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 117: 744-751.
23. UENO, H., N. KANIWA, T. OKUSAKA, M. IKEDA, C. MORIZANE et al., 2009 Homozygous CDA*3 is a major cause of lifethreatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 100: 870-873.
24. XU, J., Y. ZHOU, J. ZHANG, Y. CHEN, R. ZHUANG et al., 2012 High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. Clin Chim Acta 413: 1284-1287.
25. YONEMORI, K., H. UENO, T. OKUSAKA, N. YAMAMOTO, M. IKEDA et al., 2005 Severe drug toxicity associated with a singlenucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11: 2620-2624.
26. ZHANG, J., X. WANG, C.-J. LIN, F. J. COUCH and P. FEI, 2006 Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ther 5: 1632-1636.